CA3077421A1 - Inhalable composition of clofazimine and methods of use thereof - Google Patents

Inhalable composition of clofazimine and methods of use thereof Download PDF

Info

Publication number
CA3077421A1
CA3077421A1 CA3077421A CA3077421A CA3077421A1 CA 3077421 A1 CA3077421 A1 CA 3077421A1 CA 3077421 A CA3077421 A CA 3077421A CA 3077421 A CA3077421 A CA 3077421A CA 3077421 A1 CA3077421 A1 CA 3077421A1
Authority
CA
Canada
Prior art keywords
clofazimine
composition
pharmaceutical composition
particles
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3077421A
Other languages
English (en)
French (fr)
Inventor
Hugh Smyth
Ashlee BRUNAUGH
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3077421A1 publication Critical patent/CA3077421A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3077421A 2017-10-02 2018-10-02 Inhalable composition of clofazimine and methods of use thereof Pending CA3077421A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566633P 2017-10-02 2017-10-02
US62/566,633 2017-10-02
PCT/US2018/053947 WO2019070693A1 (en) 2017-10-02 2018-10-02 COMPOSITION FOR INHALING CLOFAZIMINE AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CA3077421A1 true CA3077421A1 (en) 2019-04-11

Family

ID=65995179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3077421A Pending CA3077421A1 (en) 2017-10-02 2018-10-02 Inhalable composition of clofazimine and methods of use thereof

Country Status (8)

Country Link
US (2) US20200297626A1 (https=)
EP (1) EP3691646A4 (https=)
JP (2) JP2020536123A (https=)
CN (1) CN111212645A (https=)
AU (2) AU2018345609A1 (https=)
BR (1) BR112020006609A2 (https=)
CA (1) CA3077421A1 (https=)
WO (1) WO2019070693A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112279815A (zh) * 2019-07-22 2021-01-29 中国食品药品检定研究院 一种氯法齐明盐类化合物及其制备方法和用途
CN121221570A (zh) * 2019-11-06 2025-12-30 曼金德公司 氯法齐明的组合物，含它们的组合，它们的制备方法，含它们的用途和治疗方法
AU2021263580A1 (en) * 2020-05-01 2022-11-24 Mannkind Corporation Clofazimine composition and method for the treatment or prophylaxis of viral infections
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
US20240299379A1 (en) * 2021-06-01 2024-09-12 Board Of Regents, The University Of Texas System Compositions of clofazimine and amikacin for pulmonary administration in the treatment of respiratory diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
TW237386B (https=) * 1992-04-15 1995-01-01 Ciba Geigy
EP2168571B1 (en) * 2000-11-30 2018-08-22 Vectura Limited Particles for use in a Pharmaceutical Composition
EP2200613B1 (en) * 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
GB0803969D0 (en) * 2008-03-04 2008-04-09 Britannia Pharmaceuticals Ltd Improved phospholipid and method for its production
CN107596518B (zh) * 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
KR101466616B1 (ko) * 2012-10-11 2014-11-28 한미약품 주식회사 건조분말 흡입장치
WO2016081825A1 (en) * 2014-11-21 2016-05-26 KamTek, Inc. Methods and compositions for treating clostridium difficile associated disease
WO2016123530A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents
JP6773675B2 (ja) * 2015-03-11 2020-10-21 アレックザ ファーマシューティカルズ， インコーポレイテッド サーマルエアゾール凝縮プロセスのためのエアウェイにおける帯電防止材の使用
WO2016196401A1 (en) * 2015-05-29 2016-12-08 The Texas A&M University System Antimicrobial and anti-inflammatory compositions
JP6953414B2 (ja) * 2016-01-20 2021-10-27 フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法

Also Published As

Publication number Publication date
WO2019070693A1 (en) 2019-04-11
AU2018345609A1 (en) 2020-04-16
AU2024205572A1 (en) 2024-08-22
JP2023171770A (ja) 2023-12-05
EP3691646A4 (en) 2021-06-30
US20200297626A1 (en) 2020-09-24
BR112020006609A2 (pt) 2020-10-06
JP2020536123A (ja) 2020-12-10
EP3691646A1 (en) 2020-08-12
US20240099967A1 (en) 2024-03-28
CN111212645A (zh) 2020-05-29

Similar Documents

Publication Publication Date Title
US20240099967A1 (en) Inhalable composition of clofazimine and methods of use thereof
US10987357B2 (en) Aerosolized fluoroquinolones and uses thereof
JP6082049B2 (ja) 閉塞性または炎症性気道疾患を治療するための２種以上の活性成分を含有する粒子の乾燥粉末製剤
JP5279487B2 (ja) エアロゾル化フルオロキノロンおよびその使用
US12076328B2 (en) Pharmaceutical compositions of niclosamide
US20060276483A1 (en) Aerosolized fluoroquinolones and uses thereof
US20160128972A1 (en) Method for preventing influenza virus infection by administering a dry powder pharmaceutical composition
AU2013203605B2 (en) Aerosolized fluoroquinolones and uses thereof
US20240299379A1 (en) Compositions of clofazimine and amikacin for pulmonary administration in the treatment of respiratory diseases
US20220047604A1 (en) Aerosolized fluoroquinolones and uses thereof
CN120322221A (zh) 用于吸入的包含糖和脂质复合颗粒的结晶药物组合物及其制备方法
HK1160004B (en) Dry powder pharmaceutical composition for inhalation
HK1160004A (en) Dry powder pharmaceutical composition for inhalation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230929

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250903

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260402